The efficacy of autologous bone marrow-derived stem cell injections in refractory plantar fasciitis
[Medipana News 2019-12-5] Study on the Efficacy of Autologous Bone Marrow-Derived Stem Cell Injections for Intractable Plantar Fasciitis A Prospective, Randomized, Controlled TrialDong-Woo Shim, Department of Orthopedics, International St. Mary’s HospitalPlantar fasciitis is a common, chronic foot condition that can lead to functional impairment. While the exact pathophysiology remains unknown, increased proximal fascial thickness, decreased blood flow, peritendon inflammation, and changes in pain receptors are believed to contribute to the symptoms. Pain is typically most severe with the first step in the morning, persisting or improving throughout the day, and worsening during daily activities. Bilateral plantar fasciitis occurs in 10% of patients, and more than 80% improve within one year with conservative treatment alone. Given this natural course, most patients improve without specific treatment. However, approximately 10% of patients who receive conservative treatment experience persistent pain. Therefore, patients complaining of hindfoot pain are treated with stretching exercises, shoe correction, steroid injections, autologous blood injections, extracorporeal shock wave therapy, nighttime orthotics, and non-inflammatory analgesics. If these conservative treatments fail to improve symptoms, surgical treatments such as plantar fascia release may be considered. However, the pros and cons of these treatments vary widely among authors.Stem cell therapy has recently gained attention and has been proposed as a treatment option for osteochondral injuries of the talus. While clinical data are limited, Ambrosi et al. reported significant clinical improvement after administering autologous adipose-derived stem cells to four patients with talar osteochondral injuries. However, there are no studies on the efficacy of stem cell therapy for tendon inflammation, such as plantar fasciitis. This study aims to report on the differences in treatment outcomes between stem cell therapy and other treatments for patients with refractory plantar fasciitis, in whom symptoms persist despite appropriate conservative treatment. 1. If you agree to participate in the study, blood tests, an electrocardiogram, and a chest X-ray will be performed to assess your overall health, similar to traditional surgical preparation. This study will involve a total of 18 participants. The expected follow-up period is 12 months. Four hospital visits will be required during this period: at 6 weeks, 3 months, 6 months, and 1 year. The medications and devices used in this clinical study are supplied by Miracell Co., Ltd., and are used to extract autologous bone marrow-derived stem cells for the purpose of regenerating cartilage in patients with cartilage damage. This device is a medical device approved by the Ministry of Food and Drug Safety for the treatment of cartilage damage. This clinical study will evaluate its effectiveness in treating inflammation in tendons and tendon tissues, including the fascia. For inquiries, contact: Dong-Woo Shim, Department of Orthopedics, International St. Mary’s Hospital Email: dcastle@hanmail.net <ⓒ 2019 Medipana News. Unauthorized reproduction and distribution prohibited>Medipana News, the “center of Korean medical news.”
Miracell, boosting immunity with stem cell intravenous injections. Miracell, boosting immunity with stem cell intravenous injections.
[Financial News 2020.02.26] Miracell boosts immunity with intravenous stem cell injections. [Financial News] With much attention focused on strengthening immunity to prevent COVID-19, there are cases where immunity was enhanced through intravenous stem cell injections. Dr. Choi Dong-jin, director of Selfia Clinic, announced on the 26th that a patient complaining of chronic fatigue and physical decline experienced an increase in NK cell counts after receiving stem cell treatment from Miracell.NK cells actively seek out cancer cells or virus-infected cells and induce their apoptosis or necrosis. Numerous studies have concluded that NK cells inhibit cancer progression not through their numbers, but through their activity. The procedure involves extracting 240cc of the patient’s blood, separating and concentrating it, extracting stem cells, and then injecting them intravenously. Stem cells can create cells with the same capabilities as themselves through cell division. This regenerative ability allows them to regenerate body tissues and organs. Dr. Choi compared immune cell activity by testing NK cell activity 10 days after the intravenous stem cell injection. The immune cell count before the stem cell injection was 447.6, while the count after the injection was 1542.2, representing a nearly threefold increase. Director Choi explained that to enhance NK cell activity, it is recommended to combine stem cell injections with regular exercise, adequate sleep and rest, hydration, and antioxidant intake. Pompom@fnnews.com, Reporter Jeong Myeong-jin
Miracell Launches Cell Storage Service Rental Product
[Maeil Business Newspaper, March 16, 2020] Miracell Co., Ltd. Launches Immune Cell and Stem Cell Storage Rental Products to Strengthen Immunity Stem cell specialist Miracell Co., Ltd. (CEO Shin Hyeon-sun) and rental service specialist Barorental (CEO Lee Hyeong-bae) announced the official launch of a 20-year cell storage rental service (‘Immune Cell/Stem Cell Barobaro Care’) to strengthen immunity and provide healthcare. The newly launched “Cell Storage Rental Service” is a service that isolates stem cells and immune cells from healthy adults and freezes them for 20 years. This service is a future-oriented healthcare service that preserves the body’s immune system, which plays a crucial role in the fight against infectious diseases like COVID-19, SARS, and MERS. By launching Korea’s first “immune cell/stem cell storage rental product,” CEO Lee Hyung-bae of Barorental Co., Ltd. has dedicated himself to minimizing customer costs and making cell storage rental products more accessible to a wider audience. He expressed his hope that this service will help people overcome health concerns and anxiety about future illnesses during these challenging times, and expressed his ambition to introduce the “cell storage rental product” through various channels. Shin Hyun-soon, CEO of Miracell, a domestic stem cell company, said, “The efforts to popularize and expand regenerative medicine using stem cells and immune cells over the past decade have recently been re-evaluated due to the COVID-19 pandemic.” He added, “Government support is urgently needed to revitalize the future bio-regenerative medicine market. Furthermore, as infectious diseases like the current one spread, we must devise measures to protect our health.” He emphasized that now, with the growing sense of crisis surrounding individual immunity, is the perfect time to store healthy immune cells to prepare for unknown diseases that may arise in the future. Detailed information on cell storage rental products can be found on the official websites of Miracell and Barorental. [ⓒ Maeil Business Newspaper & mk.co.kr, Unauthorized reproduction and redistribution prohibited]